Westwood Holdings Group’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
AIM
OAG
GP
SOCM
Westwood Holdings Group's CRSP Position: Q1 2026 in Review
Westwood Holdings Group reduced its CRISPR Therapeutics (CRSP) stake by 10% in Q1 2026, selling an estimated $130K and leaving 21,453 shares worth $1.02M. The position accounts for 0.01% of the portfolio, ranked #349.
Westwood Holdings Group first reported a position in CRSP in Q2 2021 and has held it in 20 quarters since. The position peaked at $7.95M in Q3 2023. 490 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- Westwood Holdings Group held 21,453 shares of CRISPR Therapeutics worth $1.02M as of Q1 2026.
- Westwood Holdings Group sold 2,462 CRISPR Therapeutics shares in Q1 2026, an estimated $130K.
- CRISPR Therapeutics made up 0.01% of Westwood Holdings Group's portfolio in Q1 2026, its #349 holding.
- Westwood Holdings Group first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 20 quarters since.
- Westwood Holdings Group's CRISPR Therapeutics position peaked at $7.95M in Q3 2023.
- 490 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on Westwood Holdings Group's 13F filing for Q1 2026, filed 15 May 2026.